← Back to Search

Riociguat for Sarcoidosis (RioSAPH Trial)

Phase 4
Waitlist Available
Led By Steve Nathan, MD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 48 weeks
Awards & highlights
All Individual Drugs Already Approved
Drug Has Already Been Approved
Approved for 5 Other Conditions
Pivotal Trial

Summary

This trial tests riociguat, a drug that relaxes lung blood vessels, on patients with high lung blood pressure due to sarcoidosis. The goal is to see if it can help reduce lung pressure and improve heart function. Riociguat is already approved for treating certain types of high lung blood pressure in adults.

Eligible Conditions
  • Sarcoidosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Time until clinical worsening
Secondary study objectives
Pulmonary function
Quality of life
Safety: adverse events
+1 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: RiociguatActive Control1 Intervention
Active drug
Group II: PlaceboPlacebo Group1 Intervention
placebo

Find a Location

Who is running the clinical trial?

University of CincinnatiLead Sponsor
435 Previous Clinical Trials
635,278 Total Patients Enrolled
14 Trials studying Sarcoidosis
3,712 Patients Enrolled for Sarcoidosis
Steve Nathan, MDPrincipal InvestigatorInova Fairfax Hospital
Robert P Baughman, MDPrincipal InvestigatorUniversity of Cincinnati
10 Previous Clinical Trials
2,530 Total Patients Enrolled
9 Trials studying Sarcoidosis
2,515 Patients Enrolled for Sarcoidosis
~6 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top